<?xml version="1.1" encoding="utf-8"?>
<article xsi:noNamespaceSchemaLocation="http://jats.nlm.nih.gov/publishing/1.1/xsd/JATS-journalpublishing1-mathml3.xsd" dtd-version="1.1" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><front><journal-meta><journal-id journal-id-type="publisher-id">JCNR</journal-id><journal-title-group><journal-title>Journal of Clinical and Nursing Research</journal-title></journal-title-group><issn>2208-3685</issn><eissn>2208-3693</eissn><publisher><publisher-name>Bio-Byword Scientific Publishing Pty. Ltd.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.26689/jcnr.v9i3.10120</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title>The Efficacy of Whole-Course Local Simultaneous Integrated Boost Intensity-Modulated Radiotherapy in the Treatment of Locally Advanced Esophageal Cancer and Its Impact on Immune Function</title><url>https://artdesignp.com/journal/JCNR/9/3/10.26689/jcnr.v9i3.10120</url><author>YuanLei,GaoYujuan</author><pub-date pub-type="publication-year"><year>2025</year></pub-date><volume>9</volume><issue>3</issue><history><date date-type="pub"><published-time>2025-04-04</published-time></date></history><abstract>Objective: To analyze the efficacy of whole-course local simultaneous integrated boost intensity-modulated radiotherapy (SIB-IMRT) on patients with locally advanced esophageal squamous cell carcinoma (ESCC). Methods: 88 patients with ESCC admitted to the hospital between October 2022 and October 2024 were selected and randomly divided into two groups using a random number table. The experimental group received SIB-IMRT treatment, while the control group received conventional intensity-modulated radiotherapy (C-IMRT). The objective remission rate, immune function, tumor markers, and adverse reaction rate were compared between the two groups. Results: The objective remission rate in the experimental group was higher than that in the control group (P &amp;lt; 0.05). Before treatment, there was no difference in immune function levels and tumor marker levels between the two groups (P &amp;gt; 0.05). After treatment, the immune function levels in the experimental group were better than those in the control group, and the tumor marker levels were lower than those in the control group (P &amp;lt; 0.05). The adverse reaction rate in the experimental group was lower than that in the control group (P &amp;lt; 0.05). Conclusion: SIB-IMRT can improve the objective remission rate of patients with ESCC, protect their immune function, down-regulate tumor marker levels, and prevent side effects after treatment.</abstract><keywords/></article-meta></front><body/><back><ref-list><ref id="B1" content-type="article"><label>1</label><element-citation publication-type="journal"><p>Du F, Wang G, Wei Z, 2022, Clinical Study on Concurrent Chemotherapy with Intensity-Modulated Radiotherapy and S-1 or Capecitabine in the Treatment of Advanced Esophageal Cancer in Middle-Aged and Elderly Patients. Chinese Journal of Medicine, 57(4): 389–392.</p><pub-id pub-id-type="doi"/></element-citation></ref><ref id="B2" content-type="article"><label>2</label><element-citation publication-type="journal"><p>Fu S, Jin W, Yu D, 2024, The Effect of Simultaneous Integrated Boost Intensity-Modulated Radiotherapy on Patients with Locally Advanced Esophageal Cancer. Chinese and Foreign Medical Research, 22(1): 117–120.</p><pub-id pub-id-type="doi"/></element-citation></ref><ref id="B3" content-type="article"><label>3</label><element-citation publication-type="journal"><p>Zhang W, Ren L, Jiang C, et al., 2023, The Effect of Simultaneous Integrated Boost Intensity-Modulated Radiotherapy on Locally Advanced Esophageal Cancer and Its Impact on 3-Year Survival Rate. Clinical Misdiagnosis and Mistherapy, 36(1): 41–44.</p><pub-id pub-id-type="doi"/></element-citation></ref><ref id="B4" content-type="article"><label>4</label><element-citation publication-type="journal"><p>Cao S, Zhang R, 2024, Effects of CT Simulation-Guided Three-Dimensional Conformal Intensity-Modulated Radiotherapy on Serum Tumor Markers and Quality of Life in Patients with Advanced Esophageal Cancer. Modern Medical Imaging, 33(1): 29–32.</p><pub-id pub-id-type="doi"/></element-citation></ref><ref id="B5" content-type="article"><label>5</label><element-citation publication-type="journal"><p>Wang Y, 2024, Effects of Concurrent Chemotherapy and Intensity-Modulated Radiotherapy on Serum Tumor Marker Levels and Quality of Life in Patients with Advanced Esophageal Cancer. Reflexotherapy and Rehabilitation Medicine, 5(9): 149–151, 159.</p><pub-id pub-id-type="doi"/></element-citation></ref><ref id="B6" content-type="article"><label>6</label><element-citation publication-type="journal"><p>Yang Y, Shao Y, Ma Z, et al., 2023, Effects of Intensity-Modulated Radiotherapy Combined with Chemotherapy on Imaging Findings and Quality of Life in Patients with Advanced Esophageal Cancer. Modern Medicine and Health Research (Electronic Edition), 7(8): 40–42.</p><pub-id pub-id-type="doi"/></element-citation></ref><ref id="B7" content-type="article"><label>7</label><element-citation publication-type="journal"><p>Guo Q, Guo R, Li S, 2024, Efficacy of Simultaneous Integrated Boost Intensity-Modulated Radiotherapy in the Treatment of Locally Advanced Esophageal Cancer and Its Impact on Immune Function. Jilin Medical Journal, 45(11): 2703–2706.</p><pub-id pub-id-type="doi"/></element-citation></ref><ref id="B8" content-type="article"><label>8</label><element-citation publication-type="journal"><p>Zhao Y, 2021, Clinical Application of Intensity-Modulated Radiotherapy Combined with Chemotherapy in the Treatment of Locally Advanced Non-Surgical Esophageal Cancer. Inner Mongolia Medical Journal, 53(7): 784–786.</p><pub-id pub-id-type="doi"/></element-citation></ref><ref id="B9" content-type="article"><label>9</label><element-citation publication-type="journal"><p>Yu X, 2021, Clinical Study of Intensity-Modulated Radiotherapy Combined with Cisplatin and Paclitaxel Double-Drug Concurrent Chemotherapy in the Treatment of Locally Advanced Esophageal Cancer. Clinical Medicine, 41(1): 52–54.</p><pub-id pub-id-type="doi"/></element-citation></ref><ref id="B10" content-type="article"><label>10</label><element-citation publication-type="journal"><p>Lan K, Guo R, Chen J, et al., 2024, Study on the Value of Endoscopic Titanium Clip Marking in Delineating the Target Volume During Radical Intensity-Modulated Radiotherapy for Patients with Unresectable Locally Advanced Esophageal Cancer. Chinese Journal of Medicinal Guide, 26(8): 808–813.</p><pub-id pub-id-type="doi"/></element-citation></ref><ref id="B11" content-type="article"><label>11</label><element-citation publication-type="journal"><p>Xu X, Xing Y, Zhang L, et al., 2024, Effect of Micro-Adjustment Balance Prescription No.3 on the Efficacy of Intensity-Modulated Radiotherapy for Esophageal Cancer Patients. Naval Medical Journal, 45(6): 624–628.</p><pub-id pub-id-type="doi"/></element-citation></ref><ref id="B12" content-type="article"><label>12</label><element-citation publication-type="journal"><p>Tai G, Wang G, Cui X, et al., 2024, Evaluation of the Efficacy of Simultaneous Integrated Boost Intensity-Modulated Radiotherapy and Sequential Radiotherapy in Cervical and Upper Thoracic Esophageal Cancer. Chinese Journal of Biomedical Engineering, 30(2): 130–134.</p><pub-id pub-id-type="doi"/></element-citation></ref><ref id="B13" content-type="article"><label>13</label><element-citation publication-type="journal"><p>Wang H, Guo F, Che Y, et al., 2024, Study on the Deviation Between the Center of the Intensity-Modulated Radiotherapy Plan and the Center of the Target Volume in Esophageal Cancer. China Medical Equipment, 39(11): 44–50.</p><pub-id pub-id-type="doi"/></element-citation></ref><ref id="B14" content-type="article"><label>14</label><element-citation publication-type="journal"><p>Shui M, Ye D, Wen J, et al., 2023, Effect and CT Findings of Intensity-Modulated Radiotherapy Combined with Chemotherapy in the Treatment of Esophageal Cancer. Journal of Molecular Imaging, 46(1): 83–87.</p><pub-id pub-id-type="doi"/></element-citation></ref><ref id="B15" content-type="article"><label>15</label><element-citation publication-type="journal"><p>Guo N, Wang W, Wang Y, et al., 2022, The Impact of Simultaneous Integrated Boost Intensity-Modulated Radiotherapy on the Long-Term Prognosis of Patients with Cervical and Upper Thoracic Esophageal Cancer. Chinese Journal of Radiology and Protection, 42(1): 32–39.</p><pub-id pub-id-type="doi"/></element-citation></ref></ref-list></back></article>
